GlassScriptPhysician profile
William N Mckee
NPI 1104810704
$53,797.75
in general payments reported to CMS, 2019-2025
34 companies · $751 in 2025
The $751 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $6,004 · 2021: $6,469 · 2022: $8,394 · 2023: $18K · 2024: $752 · 2025: $751.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Food and Beverage: $2,273 · Travel and Lodging: $41.92 · Education: $23.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,900.00 |
| Food and Beverage | $2,272.60 |
| Travel and Lodging | $41.92 |
| Education | $23.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $47,988.81 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Viiv Healthcare Company | $1,600.00 | 2019 | |
| Novo Nordisk INC | $1,277.45 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $621.93 | 2019-2024 | Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $333.06 | 2019-2025 | Jascayd |
| Mylan Specialty L.P. | $233.30 | 2019-2024 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $223.22 | 2021-2025 | |
| Amgen INC. | $200.38 | 2019-2025 | Otezla, Repatha, Repatha |
| Insmed, INC. | $171.24 | 2025 | Arikayce |
| Lilly USA, LLC | $155.39 | 2019-2025 | Mounjaro, Zepbound |
| Verona Pharma, INC. | $107.64 | 2025 | Ohtuvayre |
| Intuitive Surgical, INC. | $90.60 | 2024 | |
| Pfizer INC. | $87.47 | 2019-2025 | |
| Abbott Laboratories | $78.43 | 2022-2023 | Freestyle Libre 3 |
| Baxter Healthcare | $78.03 | 2023-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Monarch Airway Clearance System |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $76.14 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.23 | 2019-2024 | Xifaxan, Trulance |
| Exact Sciences Corporation | $55.12 | 2023-2025 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $51.98 | 2022-2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $41.36 | 2019 | |
| Novartis Pharmaceuticals Corporation | $35.85 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $24.78 | 2019 | |
| Genentech USA, INC. | $24.50 | 2019 | |
| Grifols USA, LLC | $23.89 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $23.65 | 2023 | Rexulti |
| Astellas Pharma US INC | $17.89 | 2020 | |
| Advanced Respiratory, INC | $17.42 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.10 | 2025 | Glassia |
| Amarin Pharma, INC. | $15.55 | 2021 | |
| Ani Pharmaceuticals, INC. | $15.34 | 2025 | Purified Cortrophin Gel |
| Viatris Specialty LLC | $14.09 | 2025 | Yupelri |
| Eisai INC. | $13.73 | 2019 | |
| Merck Sharp & Dohme LLC | $13.08 | 2019 | |
| Currax Pharmaceuticals LLC | $10.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Mckee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.